文献速递妇科

美国宫颈癌近距离放疗推量剂量与分割方案

Dose and fractionation regimen for brachytherapy boost in cervical cancer in the US.
PubMed 文献 · Gynecol Oncol · 2023-12-05

基于2020年美国国家癌症数据库,回顾性分析2018—2020年接受根治性放疗的2517例宫颈癌患者,97.3%接受高剂量率或低剂量率近距离放疗并进一步分析。高剂量率远多于低剂量率(98.9% vs 1.1%),腔内多于组织间(86.4% vs 13.6%);高剂量率分割数最常见为5次(51.0%)、4次(32.9%)、3次(8.6%)。调整后,种族、私人保险、总体保险状态和机构类型与近距离放疗分割数显著相关(分别为p<0.0001、p=0.028、p=0.001、p<0.0001,n=2184)。

要点

  • 97.3%的合格患者接受高剂量率或低剂量率近距离放疗并纳入进一步分析。
  • 高剂量率远多于低剂量率(98.9% vs 1.1%),腔内多于组织间(86.4% vs 13.6%)。
  • 高剂量率分割数最常见为5次(51.0%)、4次(32.9%)、3次(8.6%)。

核心结论

  • 在美国,高剂量率近距离放疗方案因患者和机构因素而异;未来研究可能通过将特定剂量和分割方案与患者结局相关联来优化宫颈癌近距离放疗。

研究设计与样本

  • 回顾性分析2020年美国国家癌症数据库(National Cancer Database)中2018—2020年诊断并接受根治性放疗的宫颈癌患者的临床协变量。
  • 采用逻辑回归识别患者和机构因素与近距离放疗分割数的关联,p<0.10的因素纳入多变量逻辑回归模型;除特别说明外,所有检验为双侧,显著性<0.05。

主要发现

  • 2517例合格患者中,97.3%接受高剂量率或低剂量率近距离放疗并进一步分析。
  • 高剂量率多于低剂量率(98.9% vs 1.1%),腔内多于组织间(86.4% vs 13.6%)。
  • 高剂量率最常见分割数为5次(51.0%)、4次(32.9%)、3次(8.6%)。
  • 调整其他变量后,种族、私人保险状态、总体保险状态和机构类型是与近距离放疗分割数显著相关的仅有因素(分别为p<0.0001、p=0.028、p=0.001、p<0.0001,n=2184)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Curative-intent radiotherapy for locally advanced and select early stage cervical cancer in the US includes external beam radiotherapy (EBRT) with brachytherapy. Although there are guidelines for brachytherapy dose and fractionation regimens, there are limited data on practice patterns. This study aims to evaluate the contemporary utilization of cervical cancer brachytherapy in the US and its association with patient demographics and facility characteristics. METHODS: We retrospectively analyzed clinical covariates of cervical cancer patients diagnosed and treated in 2018-2020 with curative-intent radiotherapy from the 2020 National Cancer Database. Associations between patient and institutional factors with the number of brachytherapy fractions were identified with logistic regression. Factors with association (p < 0.10) were then included in a multivariable logistic regression model. All tests were two-sided with significance <0.05 unless specified otherwise. RESULTS: Among the eligible 2517 patients, 97.3% received HDR or LDR and is further analyzed. More patients received HDR than LDR brachytherapy (98.9% vs 1.1%) and intracavitary than interstitial brachytherapy (86.4% vs 13.6%). The most common number of HDR fractions prescribed were 5 (51.0%), 4 (32.9%), and 3 (8.6%). After adjusting for the other variables in the model, ethnicity, private insurance status, overall insurance status, and facility type were the only factors that were significantly associated with the number of brachytherapy factions (p < 0.0001, p = 0.028, p = 0.001, and p < 0.0001, respectively, n = 2184). CONCLUSIONS: In the US, various HDR brachytherapy regimens are utilized depending on patient and institutional factors. Future research may optimize cervical cancer brachytherapy by correlating specific dose and fractionation regimens with patient outcomes.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Hsieh K, Bloom JR, Dickstein DR, et al. Dose and fractionation regimen for brachytherapy boost in cervical cancer in the US. Gynecol Oncol. 2023. PMID: 38052109. doi:10.1016/j.ygyno.2023.11.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。